A Phase II Trial of ProLindac and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2015
At a glance
- Drugs AP 5346 (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Access Pharmaceuticals
- 24 Jan 2015 Status changed from recruiting to completed, according to European Clinical Trials Database
- 28 Mar 2012 Planned number of patients changed from 25 to 28 and additional trial location (France) added as reported by European Clinical Trials Database.
- 03 Nov 2010 Status changed from not yet recruiting to recruiting.